Defining and quantifying histopathologic risk factors for regional and distant metastases in a large cohort of vulvar squamous cell carcinomas - 10/10/23

Abstract |
Background |
Vulvar squamous cell carcinoma (vSCC) is a rare tumor with a good prognosis when treated at a localized stage. However, once regional/distant metastasis occurs, vSCC can be rapidly fatal. Thus, it is important to identify tumor prognostic features so that high-risk cases can be prioritized for further diagnostic workup and treatment.
Objective |
To estimate the risk of regional/distant metastasis at presentation and sentinel lymph node status for vSCC based on histopathologic characteristics.
Methods |
A retrospective cohort study of 15,188 adult vSCC cases from the National Cancer Database diagnosed from 2012 to 2019.
Results |
We provide specific estimates of the risk of clinically positive nodes and metastatic disease at presentation and sentinel lymph node positivity according to tumor size, moderate/poor tumor differentiation, and lymph-vascular invasion. These histopathologic factors were all significantly associated with the tested clinical outcomes in a multivariable analysis. Moderate (hazard ratio, 1.190; P < .001) and poor differentiation (hazard ratio, 1.204; P < .001) and lymph-vascular invasion (hazard ratio, 1.465; P < .001) were also associated with significantly poorer overall survival.
Limitations |
Data on disease-specific survival not available in the data set.
Conclusions |
We demonstrate the association of the histopathologic characteristics of vSCC with clinically important outcomes. These data may provide individualized information when discussing diagnostic/treatment recommendations, particularly regarding sentinel lymph node biopsy. These data may also guide future staging and risk stratification efforts for vSCC.
Le texte complet de cet article est disponible en PDF.Key words : cutaneous, histopathologic, NCDB, risk factors, sentinel lymph node biopsy, squamous cell carcinoma, vulvar
Abbreviations used : AJCC, cSCC, HPV, HR, LVI, NCDB, OR, SLN, SLNB, vSCC
Plan
| Funding sources: None. |
|
| IRB approval status: This study was deemed not to be human subjects research and therefore exempt from IRB review by the NYU Langone IRB. |
Vol 89 - N° 5
P. 1022-1030 - novembre 2023 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
